Shares of Genfit S.A. (EPA:GNFT – Get Free Report) were up 1.1% during mid-day trading on Friday . The company traded as high as €3.84 ($4.13) and last traded at €3.69 ($3.96). Approximately 275,691 shares traded hands during trading, The stock had previously closed at €3.65 ($3.92).
Genfit Stock Performance
The company has a 50 day moving average price of €3.88 and a 200 day moving average price of €3.57.
Genfit Company Profile
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Read More
- Five stocks we like better than Genfit
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- How to Evaluate a Stock Before Buying
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.